Physician profile
Robin C Shealy
NPI 1154347540
$2,446.06
in general payments reported to CMS, 2019-2025
30 companies · $684 in 2025
The $684 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $89.78 · 2021: $418 · 2022: $455 · 2023: $347 · 2024: $211 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $703.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $289.31 | 2019-2025 | Breztri, Airsupra |
| Amgen INC. | $181.46 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $167.41 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $159.42 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $121.97 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $100.59 | 2021 | |
| Dexcom, INC. | $73.92 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $71.23 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $54.81 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $52.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $41.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $38.25 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $35.64 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $34.79 | 2025 | Jardiance, Zepbound, Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.69 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.51 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.89 | 2022-2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $29.73 | 2021-2022 | |
| Amarin Pharma, INC. | $28.87 | 2020-2021 | |
| Astellas Pharma US INC | $25.66 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $23.00 | 2023 | Rexulti |
| Acadia Pharmaceuticals INC | $18.90 | 2025 | Nuplazid |
| Cvrx, INC. | $17.86 | 2024 | Barostim Neo System |
| Hologic Sales and Service, LLC | $17.64 | 2024 | Thinprep 2000 Processor, Aptima |
| Corcept Therapeutics | $15.39 | 2025 | Korlym |
| Baxter Healthcare | $15.35 | 2022 | |
| Evofem Biosciences, INC. | $13.58 | 2021 | |
| Allergan, INC. | $11.36 | 2019 | |
| Mylan Specialty L.P. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Shealy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.